Figure 2. TSA is an effective enhancer of vaccinia in vivo.
(A) C57BL/6 mice were injected intravenously with B16F10LacZ melanoma cells (3×105 cells/mouse) and TSA (4 daily intraperitoneal doses of 0.05 mg/mouse) alone or in combination with VVdd (1×107 pfu/mouse). (B) The mice were sacrificed after 14 days and the lung metastases were counted after staining with X-gal. Asterix * indicates a P value <0.05 and is significantly different than PBS group and each of the single treatment groups. (C) Lung lobes from control or VVdd and TSA treated mice. B16F10LacZ cells stained with X-Gal. (D) Balb/C mice pre-treated or not with TSA (0.05 mg/mouse) on days 0 through 3. After 3 hr pre-treatment on day 0, mice were given an intra-venous dose of VVdd-luciferase of 1×108 pfu/mouse. One mouse per group was sacrificed at each time point and organs were titered for virus content by standard plaque assay on U2OS cells.